IVC Filter/Central Venous Catheter Combo Device; EU Launch This Week

In short

Texas-based medical device manufacturer BiO2 Medical, Inc., has announced CE Mark approval for its triple lumen Angel™ Catheter.


The Angel™ Catheter is a Nitinol, Inferior Vena Cava (IVC) filter, permanently attached to a central venous catheter (CVC) for use in preventing Pulmonary Embolism (PE) in critically ill patients. Placed at the patient’s bedside without the need for fluoroscopy, the Angel™ Catheter provides instant protection from PE and is the first IVC Filter to receive CE Mark approval for prophylactic indications.

The design of the Angel™ Catheter allows for easy insertion and access to the central venous system for administering medications, fluids, or blood products; blood sampling; and monitoring of central venous pressure. It is intended to be used during the critical time period in which anticoagulation therapy poses a high risk of complications, including major bleeding and death, and in which patients are at highest risk of VTE. The filter can be easily removed when the central line is removed, once the danger of Venous Thromboembolism has been resolved.

BiO2 Medical will introduce the Angel™ Catheter at the UK Intensive Care Society’s ‘State of the Art’ Meeting in London which is taking place this week (from December 10-12, 2012).

In a press release issued by PR Newswire the company tells us it is sponsoring a lunch symposium on Tuesday, December 11th, 2012, at the ‘State of the Art’ meeting entitled, “Improved PE Prevention in the ITU: Angel™ Catheter-Bedside IVC Filter Prophylaxis.” Chairing the symposium will be Dr. Max Jonas, Consultant Anesthetist and Intensivist at Southampton University Hospital in Southampton, UK. Speaking at the lunch symposium will be Dr. Andy Eynon, Director of Major Trauma & Neuro Intensive Care Consultant at Southampton University Hospital in Southampton, UK, and BiO2 Medical’s Chief Medical Officer, Dr. Luis Angel, inventor of the Angel™ Catheter and Associate Professor of Pulmonary and Critical Care Medicine at the University of Texas Health Science Center in San Antonio, Texas.

Company comments

According to Christopher E. Banas, BiO2 Medical’s Chairman and Chief Executive Officer, “This represents an important milestone for BiO2 Medical and the commercialization of the Angel™ Catheter. We are pleased to provide physicians with a technology that offers immediate Pulmonary Embolism protection for ICU patients during the critical unprotected window, while simultaneously allowing for lifesaving fluid and medication administration.”

Source: BiO2 Medical, Inc., PR Newswire